Jounce Therapeutics (NASDAQ:JNCE) Rating Lowered to Market Perform at Raymond James

Posted by Defense World Staff on Feb 25th, 2023

Jounce Therapeutics (NASDAQ:JNCE – Get Rating) was downgraded by equities research analysts at Raymond James from an “outperform” rating to a “market perform” rating in a research note issued to investors on Thursday, The Fly reports.

Several other equities analysts have also issued reports on JNCE. StockNews.com raised shares of Jounce Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 19th. Piper Sandler cut their price target on Jounce Therapeutics from $6.00 to $5.00 and set an “overweight” rating on the stock in a report on Tuesday, January 3rd. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $8.20.

Jounce Therapeutics Price Performance

Shares of Jounce Therapeutics stock opened at $1.15 on Thursday. The stock has a market cap of $59.44 million, a price-to-earnings ratio of -0.45 and a beta of 0.65. The firm’s 50-day moving average is $1.09 and its two-hundred day moving average is $1.94. Jounce Therapeutics has a 1 year low of $0.58 and a 1 year high of $7.94.

Institutional Investors Weigh In On Jounce Therapeutics

A number of large investors have recently modified their holdings of the business. Balyasny Asset Management LLC purchased a new stake in shares of Jounce Therapeutics during the third quarter valued at $26,000. BNP Paribas Arbitrage SA grew its holdings in shares of Jounce Therapeutics by 102.9% during the second quarter. BNP Paribas Arbitrage SA now owns 9,115 shares of the company’s stock valued at $28,000 after buying an additional 4,623 shares during the last quarter. Susquehanna International Group LLP grew its holdings in shares of Jounce Therapeutics by 824.9% during the fourth quarter. Susquehanna International Group LLP now owns 29,292 shares of the company’s stock valued at $33,000 after buying an additional 26,125 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in shares of Jounce Therapeutics during the fourth quarter valued at $40,000. Finally, Barclays PLC grew its holdings in shares of Jounce Therapeutics by 33.4% during the fourth quarter. Barclays PLC now owns 38,071 shares of the company’s stock valued at $43,000 after buying an additional 9,528 shares during the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

Jounce Therapeutics Company Profile

(Get Rating)

Jounce Therapeutics, Inc is a clinical stage immunotherapy company, which treats cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its product pipeline includes JTX-2011 (ICOS), JTX-4014 (PD-1), the Lead Macrophage Program, Macrophage Targeting, T Reg, B Cells, and Stromal Targeting.